BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Principe DR, Chiec L, Mohindra NA, Munshi HG. Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Front Oncol 2021;11:684098. [PMID: 34141625 DOI: 10.3389/fonc.2021.684098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Amgalan B, Wojtowicz D, Kim YA, Przytycka TM. Influence network model uncovers relations between biological processes and mutational signatures. Genome Med 2023;15:15. [PMID: 36879282 DOI: 10.1186/s13073-023-01162-x] [Reference Citation Analysis]
2 Anwar MM, Albanese C, Hamdy NM, Sultan AS. Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer. Cancer Cell Int 2022;22:419. [PMID: 36577970 DOI: 10.1186/s12935-022-02815-4] [Reference Citation Analysis]
3 Samarth N, Gulhane P, Singh S. Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC - A systematic review. Front Oncol 2022;12:1089320. [PMID: 36620544 DOI: 10.3389/fonc.2022.1089320] [Reference Citation Analysis]
4 Metropulos AE, Becker JH, Principe DR. Chromium (VI) promotes lung cancer initiation by activating EGF/ALDH1A1 signalling. Clinical and Translational Dis 2022;2. [DOI: 10.1002/ctd2.155] [Reference Citation Analysis]
5 Prabhakaran S, Gatenbee C, Robertson-tessi M, Beg AA, Gray J, Antonia S, Gatenby RA, Anderson ARA. Distinct tumor-immune ecologies in NSCLC patients predict progression and define a clinical biomarker of therapy response.. [DOI: 10.1101/2022.10.22.513219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pabst L, Lopes S, Kotovskaya M, Bertrand B, Mascaux C. Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé ? Revue des Maladies Respiratoires Actualités 2022;14:2S225-2S232. [DOI: 10.1016/s1877-1203(22)00122-7] [Reference Citation Analysis]
7 Xiaochun H, Feixiong P, Shengsong O, Xiaojiao W, Yuju X, Yanhua L, Schmalz G. Identification and Validation of an Inflammatory Response-Related Polygenic Risk Score as a Prognostic Marker in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/1739995] [Reference Citation Analysis]
8 Xiao W, Ahluwalia P, Wang L, Howard J, Kolhe R, Rojiani AM, Rojiani MV. TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC. Cells 2022;11:3036. [DOI: 10.3390/cells11193036] [Reference Citation Analysis]
9 Cheng C, Zhuge L, Xiao X, Luan S, Yuan Y. Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer. Front Oncol 2022;12:955163. [DOI: 10.3389/fonc.2022.955163] [Reference Citation Analysis]
10 Arasanz H, Bocanegra AI, Morilla I, Fernández-irigoyen J, Martínez-aguillo M, Teijeira L, Garnica M, Blanco E, Chocarro L, Ausin K, Zuazo M, Fernández-hinojal G, Echaide M, Fernández-rubio L, Piñeiro-hermida S, Ramos P, Mezquita L, Escors D, Vera R, Kochan G. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. Cancers 2022;14:3846. [DOI: 10.3390/cancers14163846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Mohammadi P, Hesari M, Chalabi M, Salari F, Khademi F. An overview of immune checkpoint therapy in autoimmune diseases. International Immunopharmacology 2022;107:108647. [DOI: 10.1016/j.intimp.2022.108647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee H, Chang C, Huang Y, Wu K, Chiang H, Chang Y, Liu L, Hung J, Hsu Y, Wu Y, Tsai Y. Downregulated ADAMTS1 Incorporating A2M Contributes to Tumorigenesis and Alters Tumor Immune Microenvironment in Lung Adenocarcinoma. Biology 2022;11:760. [DOI: 10.3390/biology11050760] [Reference Citation Analysis]
14 Gong Z, Li Q, Yang J, Zhang P, Sun W, Ren Q, Tang J, Wang W, Gong H, Li J. Identification of a Pyroptosis-Related Gene Signature for Predicting the Immune Status and Prognosis in Lung Adenocarcinoma. Front Bioeng Biotechnol 2022;10:852734. [DOI: 10.3389/fbioe.2022.852734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 García-pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines 2022;10:740. [DOI: 10.3390/vaccines10050740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Velut Y, Decroix E, Blons H, Alifano M, Leroy K, Petitprez F, Boni A, Garinet S, Biton J, Cremer I, Wislez M, Boudou-rouquette P, Arrondeau J, Goldwasser F, Fournel L, Damotte D, Mansuet-lupo A. SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.001] [Reference Citation Analysis]
17 Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S, Croce M. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol 2021;12:799455. [PMID: 35069581 DOI: 10.3389/fimmu.2021.799455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
18 Colarusso C, Terlizzi M, Pinto A, Sorrentino R. Drug Resistance in Lung Cancer. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_62] [Reference Citation Analysis]
19 Ly D, Li Q, Navab R, Zeltz C, Fang L, Cabanero M, Zhu CQ, Tsao MS, Zhang L. Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. Cancers (Basel) 2021;14:205. [PMID: 35008369 DOI: 10.3390/cancers14010205] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Amgalan B, Wojtowicz D, Kim Y, Przytycka TM. Influence network model uncovers relations between biological processes and mutational signatures.. [DOI: 10.1101/2021.11.16.468828] [Reference Citation Analysis]